Journal article
Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage in Fiji: results from four annual cross-sectional carriage surveys
EM Dunne, C Satzke, FT Ratu, EFG Neal, LK Boelsen, S Matanitobua, CL Pell, ML Nation, BD Ortika, R Reyburn, K Jenkins, C Nguyen, K Gould, J Hinds, L Tikoduadua, J Kado, E Rafai, M Kama, EK Mulholland, FM Russell
Lancet Global Health | ELSEVIER SCI LTD | Published : 2018
Open access
Abstract
Background: The indirect effects of pneumococcal conjugate vaccines (PCVs) are mediated through reductions in carriage of vaccine serotypes. Data on PCVs in Asia and the Pacific are scarce. Fiji introduced the ten-valent PCV (PCV10) in 2012, with a schedule consisting of three priming doses at 6, 10, and 14 weeks of age and no booster dose (3 + 0 schedule) without catch-up. We investigated the effects of PCV10 introduction using cross-sectional nasopharyngeal carriage surveys. Methods: We did four annual carriage surveys (one pre-PCV10 and three post-PCV10) in the greater Suva area in Fiji, during 2012–15, of 5–8-week-old infants, 12–23-month-old children, 2–6-year-old children, and their ca..
View full abstractGrants
Awarded by Bill and Melinda Gates Foundation
Funding Acknowledgements
This study was supported by the Bill & Melinda Gates Foundation (OPP1084341 and OPP1126272), the Department of Foreign Affairs and Trade of the Australian Government, and Fiji Health Sector Support Programme. This programme is implemented by Abt JTA on behalf of the Australian Government.